Search

Displaying results 31 - 40 of 58 in total
  1. Indication

    Metastatic Gastric Cancers

    go.drugbank.com/conditions/DBCOND0063580
    Drugs: Hyaluronidase (human recombinant) · Nivolumab · Trifluridine
  2. Indication

    Inflammatory Breast Cancer (IBC)

    go.drugbank.com/conditions/DBCOND0084733
    Drugs: Hyaluronidase (human recombinant) · Pertuzumab · Trastuzumab
  3. Indication

    Locally Advanced Urothelial Cancer

    go.drugbank.com/conditions/DBCOND0113982
    Drugs: Enfortumab vedotin · Hyaluronidase (human recombinant) · Nivolumab
  4. Indication

    Resectable Non-small Cell Lung Cancer

    go.drugbank.com/conditions/DBCOND0068626
    Drugs: Durvalumab · Hyaluronidase (human recombinant) · Nivolumab · Pembrolizumab
  5. Indication

    Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)

    go.drugbank.com/conditions/DBCOND0144294
    Drugs: Cetuximab · Hyaluronidase (human recombinant) · Nivolumab · Pembrolizumab
  6. Indication

    Metastatic Esophageal Adenocarcinoma

    go.drugbank.com/conditions/DBCOND0125777
    Drugs: Hyaluronidase (human recombinant) · Nivolumab · Tislelizumab · Zanidatamab
  7. Drug

    Pertuzumab

    go.drugbank.com/drugs/DB06366
    ApprovedInvestigational

    Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2).

    Categories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
  8. Indication

    Metastatic Urothelial Carcinoma (UC)

    go.drugbank.com/conditions/DBCOND0073677
    Drugs: Durvalumab · Hyaluronidase (human recombinant) · Nivolumab · Pembrolizumab · Pemetrexed
  9. Indication

    Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

    go.drugbank.com/conditions/DBCOND0138147
    Drugs: Cetuximab · Docetaxel · Hyaluronidase (human recombinant) · Nivolumab · Pembrolizumab
  10. Drug

    Ocrelizumab

    go.drugbank.com/drugs/DB11988
    ApprovedInvestigational

    [A31741] In September 2024, a formulation of ocrelizumab containing [hyaluronidase (human recombinant)] was approved by the US FDA. … The addition of hyaluronidase allows for subcutaneous injection, which is a method often preferable for patients and provides an alternative means of administration for sites lacking IV infrastructure,